NCT02757859
WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer
Active, Not Recruiting
NAAges 18+InterventionalTreatmentSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityInvestigator-initiated
~845 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:PancreatectomyLavage
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival
Measured over Up to 27 months after resection
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Harish Lavu, MD · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
The subject has a surgical indication for pancreatectomy (pancreaticoduodenctomy, distal pancreatectomy, total pancreatectomy) as determined by the treating physician/surgeon
A diagnosis of pancreatic or other periampullary cancer is suspected preoperatively
In the opinion of the surgeon, the subject has no medical contraindications to pancreatectomy
Age ≥18 years of age.
The subject is willing to consent to randomization of EAL-S vs. EAL-W vs. no extensive lavage (SOC)
Exclusion
The subject does not have a surgical indication for pancreatectomy
In the opinion of the surgeon, the subject has medical contraindications to pancreatectomy
Age \<18 years of age
The subject is not willing to consent to EAL-S vs. EAL-W vs. no extensive lavage (SOC)
Known benign or indolent disease (including benign pancreatic cystic tumors or pancreatic endocrine tumors) without possible risk of malignancy
Other malignancy within five years, unless the probability of recurrence of the prior malignancy is \<5% as determined by the Principal Investigator based on available information. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
Evidence of metastatic disease preoperatively
What this trial measures
- Overall SurvivalUp to 27 months after resection
Will use a one-sided log-rank test to separately compare lavage (EAL-S or EAL-W) to no lavage with respect to OS. Assuming the study is not stopped at the interim analyses, the final comparison will be made with an alpha level of 0.02493. Distribution of OS will be estimated using the Kaplan-Meier method. Secondary analyses will use Cox regression to adjust the lavage/no lavage comparison for other baseline patient and/or characteristics known to be associated with OS.